

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/G5DC8342596EN.html>

Date: November 2019

Pages: 148

Price: US\$ 2,000.00 (Single User License)

ID: G5DC8342596EN

Abstracts

Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2019, provides an overview of the Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) pipeline landscape.

Gorlin syndrome, also known as nevoid basal cell carcinoma syndrome, is a condition that affects many areas of the body and increases the risk of developing various cancerous and noncancerous tumors. Symptoms include arrhythmia, medulloblastoma, ovarian fibromas, depressions in the skin, large head size and skeletal abnormalities involving the spine, ribs, or skull. Treatment includes surgery, radiotherapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gorlin Syndrome (Basal Cell Nevus Syndrome/Nevoid Basal Cell Carcinoma Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Discovery stages are 1, 3, 1 and 2 respectively.

Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology).

The pipeline guide reviews pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) therapeutics and enlists all their major and

minor projects.

The pipeline guide evaluates Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Gorlin Syndrome (Basal Cell Nevus Syndrome) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Overview

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Companies Involved in Therapeutics Development

Adgero Biopharmaceuticals Holdings Inc

Feldan Therapeutics Inc

Galderma SA

Genentech Inc

Mayne Pharma Group Ltd

Ono Pharmaceutical Co Ltd

PellePharm Inc

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Drug Profiles

FTX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itraconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patidegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rostaporfin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trifarotene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vismodegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Dormant Projects

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Discontinued Products

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Product Development Milestones

Featured News & Press Releases

Apr 01, 2019: PellePharm initiates pivotal phase 3 clinical trial of Patidegib topical gel in patients with gorlin syndrome

Dec 18, 2018: Mayne Pharma announces US commercial rights for Suba-itraconazole in BCCNS

Oct 15, 2018: Pellepharm presents updated data from two phase 2 studies demonstrating the potential of Patidegib topical gel to treat basal cell carcinomas in patients with gorlin syndrome and in patients with non-gorlin sporadic bccs

Oct 11, 2018: HedgePath Pharmaceuticals to present at the 2018 BioFlorida Annual Conference

Oct 09, 2018: HedgePath Pharmaceuticals pathway for filing SUBA BCCNS NDA clarified in Meeting with FDA

Jun 05, 2018: HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway

May 16, 2018: PellePharm to present topical Patidegib and skin cancer epidemiological data at the 7th International Investigative Dermatology Meeting

Feb 22, 2018: Adgero Biopharmaceuticals Granted FDA Orphan Drug Designation of REM-001 Therapy for the Treatment of Basal Cell Carcinoma Nevus Syndrome

Jan 11, 2018: HedgePath Pharmaceuticals Receives Orphan Drug Designation for SUBA-Itraconazole from the European Medicines Agency

Nov 20, 2017: FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to Pellepharm for Topical Patidegib in Gorlin Syndrome

Oct 30, 2017: HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update

Jul 31, 2017: PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas

Jul 25, 2017: HedgePath Pharmaceuticals Receives Clarity From FDA Regarding Pathway to Potential Regulatory Submission

May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update

Apr 10, 2017: Positive Clinical Data of Adgero Biopharmaceuticals' REM-001 Therapy for the Treatment of Cutaneous Metastatic Breast Cancer Presented at 37th ASLMS Annual Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Feldan Therapeutics Inc, H2 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Galderma SA, H2 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Genentech Inc, H2 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Mayne Pharma Group Ltd, H2 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Pipeline by PellePharm Inc, H2 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Dormant Projects, H2 2019

Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Adgero Biopharmaceuticals Holdings Inc

Feldan Therapeutics Inc

Galderma SA

Genentech Inc

Mayne Pharma Group Ltd

Ono Pharmaceutical Co Ltd

PellePharm Inc

I would like to order

Product name: Gorlin Syndrome (Basal Cell Nevus Syndrome) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/G5DC8342596EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5DC8342596EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970